GlobeNewswire

FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

Share

Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines.

The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.  The review was also conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology products among international partners.

"When receiving a cancer immunotherapy combined with targeted therapies, patients with BRAF V600 mutation-positive advanced melanoma were able to live for more than 15 months without their disease worsening," said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. "Today’s FDA approval of this Tecentriq combination represents an important step forward for many patients living with advanced melanoma."

The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without disease worsening or death compared to placebo plus Cotellic and Zelboraf (median PFS 15.1 months versus 10.6 months respectively; hazard ratio, HR=0.78; confidence interval: 0.63-0.97; P=0.025).  The most common adverse reactions (rate ≥20%) in patients who received Tecentriq plus Cotellic and Zelboraf were rash (75%), musculoskeletal pain (62%), fatigue (51%), hepatotoxicity (50%), pyrexia (49%), nausea (30%), pruritus (26%), edema (26%), stomatitis (23%), hypothyroidism (22%), and photosensitivity reaction (21%).

Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

About the IMspire150 study
IMspire150 is a Phase III, multi-center, double-blind, placebo-controlled randomised study in people with previously untreated BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma. The study compared the efficacy and safety of Tecentriq plus Cotellic and Zelboraf to the combination of placebo plus Cotellic and Zelboraf. The primary endpoint of the study was investigator-assessed PFS. Key secondary endpoints include PFS by an independent review committee, overall survival, objective response rate, duration of response and other safety and pharmacokinetic measures.

Five hundred and fourteen adult patients took part in the study. Randomisation was stratified by lactate dehydrogenase (LDH) level and geographic region. Eligible patients were randomised 1:1 to one of two treatment groups, to receive 28-day cycles of either: Tecentriq plus Cotellic and Zelboraf (the Tecentriq group) or Placebo plus Cotellic and Zelboraf (the control group). In cycle 1, all patients received once-daily oral Cotellic 60 mg plus twice-daily oral Zelboraf 960 mg for 21 days followed by twice-daily Zelboraf 720 mg or 960 mg for 7 days in the Tecentriq group or control group, respectively. Patients in the Tecentriq group received Zelboraf 720 mg Days 1–28 of each subsequent cycle. The lower 720 mg dose of Zelboraf in the Tecentriq group was a safety measure to mitigate the risk of overlapping toxicities, while ensuring an efficacious dose of Zelboraf. Treatment was continued until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, whichever occurred first.

About advanced melanoma
Melanoma is a less common, but more aggressive and potentially deadly form of skin cancer.1,2 When melanoma is diagnosed early, it is generally a curable disease,3,4 but most people with advanced melanoma have a poor prognosis.2 More than 287,000 people worldwide are currently diagnosed with melanoma each year.5 BRAF is mutated in approximately half of melanomas.6 In recent years, there have been significant advances in treatment for advanced melanoma and people with the disease have more options. However, it continues to be a serious health issue with a high medical need and a steadily increasing incidence over the past 30 years.7

About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Cotellic (cobimetinib)
Cotellic is designed to inhibit MEK1/2, proteins in a cell signaling pathway that helps control cell growth and survival. Cotellic, when used in combination with Zelboraf, is approved in the United States and Europe, as well as many countries around the world, for the treatment of people with melanoma that has spread to other parts of the body or cannot be removed by surgery and has a BRAF V600 mutation. Cotellic was discovered by Exelixis and is being developed by Genentech, a member of the Roche Group, in collaboration with Exelixis.

About Zelboraf (vemurafenib)
Zelboraf is a prescription medicine for the treatment of people with melanoma that has spread to other parts of the body or cannot be removed by surgery and has a BRAF V600 mutation. Zelboraf is designed to inhibit some mutated forms of BRAF, which cause abnormal signaling inside cancer cells leading to tumor growth. BRAF is a protein in a cell signaling pathway that helps control cell growth and survival. Zelboraf was the first approved product in its class. Zelboraf was co-developed under a 2006 license and collaboration agreement between Roche and Plexxikon Inc., the small molecule structure-guided R&D center of the Daiichi Sankyo Group.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Algazi AP, et al. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010;2:197-211
[2] Finn L, et al. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 2012;10:23.
[3] Leong SP. Future perspectives on malignant melanoma. Surg Clin North Am. 2003;83:453-6.
[4] Creagan ET. Malignant melanoma: an emerging and preventable medical catastrophe. Mayo Clin Proc. 1997;72:570-4.
[5] Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today/home Last accessed: July 2020.
[6] Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
[7] Bataille V. Risk factors for melanoma development. Expert Rev Dermatol. 2009;4:533-9

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES20.10.2020 09:30:00 CESTPress release

AUCTION DATE:OCT 20, 2020START DATE:OCT 21, 2020MATURITY DATE:OCT 28, 2020NOMINAL AMOUNT:380.0 BLNFIXED RATE:0.00 % PROJECTED LIQUIDITY SURPLUS FOR THE PERIOD OCT 21-28 2020: 868.5 BLN SEK. AT FULL ALLOTMENT EXCESS LIQUIDITY WILL AMOUNT TO APPROXIMATELY 488.5 BLN SEK FOR THE PERIOD OCT 21-28 2020. ALL MONETARY POLICY COUNTERPARTIES ARE INVITED TO SUBMIT BIDS TO THE RIKSBANK (08-6966970) BY 10.00 AM ON OCT 20 2020 AT THE LATEST. CONFIRMATION OF BIDS TO E-MAIL: RBCERT@riksbank.se THE LOWEST ACCEPTED BID VOLUME IS SEK 1 MLN. THE HIGHEST ACCEPTED BID VOLUME IS SEK 380.0 BLN. RESULT OF AUCTION WILL BE PUBLISHED AT 10.15 (CEST) ON OCT 20 2020. COMPLETE TERMS AND CONDITIONS CAN BE RETRIEVED AT WWW.RIKSBANK.SE

Invitation to UPM’s webcast and press conference on Q3 2020 Interim Report20.10.2020 09:00:00 CESTPress release

(UPM, Helsinki, 20 October 2020 at 10:00 EET) – UPM will publish its third quarter results on 27 October 2020 at 09:30-10:00 EET. After publishing the report will be available on company's website at www.upm.com. A webcast and a conference call for analysts and investors in English language begins at 13:15 EET. UPM’s financial results will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. All participants can view the webcast online at www.upm.com or through this link, but participants who wish to ask questions must attend the conference call by dialling a number in the list below: Conference call title: UPM Interim Report for January – September 2020 International telephone numbers: Australia Toll: +61 284058549 Austria Toll: +43 19287907 Belgium Toll: +32 24035814 Denmark Toll: +45 35445577 Finland Toll: +358 981710310 France Toll: +33 170750711 Germany Toll: +49 6913803430 Hong Kong Toll: +852 30600225 India Toll: +91 2271279610 Ireland Toll: +353 14311252

Participation Notification by Blackrock Inc.20.10.2020 08:30:00 CESTPress release

Participation notification by Blackrock Inc. Brussels, October 20, 2020, 08:30 CEST - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalOctober 13, 20202.97%0.15%3.12%October 15, 20203.03%0.10%3.12% The latest notification, dated October 19, 2020, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: October 15, 2020Threshold of direct voting rights crossed: 3% upwardsDenominator: 105,876,416Additional information: The disclosure obligation aro

Yara delivers improved returns, proposes additional dividend20.10.2020 08:00:00 CESTPress release

Oslo, 20 October 2020: Yara delivers improved third-quarter results, with record NPK deliveries, improved capital returns and increased cash flow. Net income was USD 340 million (USD 1.27 per share) compared with USD 74 million (USD 0.27 per share) a year earlier. The main elements of the third-quarter results are: NOK 18 per share additional dividend proposed; total NOK 53 per share cash returns1 paid or committed to shareholders in 20207.9% ROIC2, up from 6.1% a year earlierEBITDA3 down 11%, mainly reflecting lower nitrogen pricesRecord NPK deliveriesUSD 2.5 billion free cashflow4 rolling 4 quarters “Yara delivers its ninth consecutive quarter with improved capital returns, despite our results being impacted by lower nitrogen prices. Our crop nutrition focused business model continues to perform strongly, delivering record NPK volumes in the quarter. I would like to give credit to the entire Yara organisation for another solid effort in a demanding environment,” said Svein Tore Holse

Yara leverer økt kapitalavkastning og foreslår tilleggsutbytte20.10.2020 08:00:00 CESTPressemelding

Oslo, 20. oktober 2020: Yara leverer økt tredjekvartalsresultat, med rekordhøye NPK-leveranser, økt kapitalavkastning og økt kontantstrøm. Nettoresultatet var USD 340 millioner (USD 1,27 per aksje) mot USD 74 millioner (USD 0,27 per aksje) et år tidligere. Hovedelementene i resultatet for tredje kvartal er: NOK 18 per aksje i tilleggsutbytte foreslås; totalt 53 kroner kontantavkastning1 per aksje betalt eller forpliktet til aksjonærer i 20207,9 % ROIC2, opp fra 6,1 % ett år tidligereEBITDA3 ned 11 %, hovedsakelig grunnet lavere nitrogenpriserRekordhøye NPK-leveranserUSD 2,5 milliarder fri kontantstrøm4 siste 4 kvartal «Yara leverer sitt niende kvartal med økt kapitalavkastning, til tross for at resultatet påvirkes av lavere nitrogenpriser. Vår premium-fokuserte forretningsmodell fortsetter å levere, med rekordhøye NPK-leveranser i kvartalet. Jeg vil takke hele Yara-organisasjonen for nok et solid kvartal i et krevende marked», sier Svein Tore Holsether, konsernsjef i Yara. «Vår kontant

Sdiptech AB (publ) tidigarelägger publicering av delårsrapport för tredje kvartalet till den 22 oktober 202020.10.2020 08:00:00 CESTPressemelding

Pressmeddelande 20 oktober 2020, 08:00 Sdiptech tidigarelägger publicering av delårsrapport för tredje kvartalet till den 22 oktober 2020 Sdiptech har beslutat att tidigarelägga publicering av delårsrapporten avseende det tredje kvartalet, då färdigställandet av rapporten gått snabbare än beräknat. Nytt datum för publicering är torsdagen den 22 oktober 2020. Tidigare aviserad tidpunkt var tisdagen den 3 november 2020. Sdiptech offentliggör sin delårsrapport för det tredje kvartalet 2020, torsdagen den 22 oktober 2020, kl. 08:00, och bjuder in till en presentation via en webbsändning samma dag kl. 14.00. Sdiptechs VD Jakob Holm och CFO Bengt Lejdström kommer att presentera delårsrapporten samt svara på frågor. Presentationen hålls på engelska. Presentationen webbsänds Sändningen går att följa via följande länk: https://www.finwire.tv/webcast/sdiptech/q3/ De presentationsbilder som används kommer att finnas tillgängliga under webbsändningen och kommer även att publiceras på bolagets hems